Related Experiment Videos
[Aspirin and antiphospholipid syndrome]
E Hachulla1, A M Piette, P Y Hatron
1Service de médecine interne, hôpital Huriez, CHRU, Lille, France.
La Revue De Medecine Interne
|April 14, 2000
Summary
Low-dose aspirin effectively prevents pregnancy loss in antiphospholipid antibody syndrome. However, its role in preventing arterial or venous thrombosis requires further investigation through prospective studies.
Area of Science:
- Rheumatology
- Hematology
- Obstetrics
Background:
- Antiphospholipid syndrome is a leading cause of acquired thrombophilia.
- Aspirin's efficacy is established for obstetric complications in antiphospholipid antibody syndrome.
- Heparin combined with low-dose aspirin reduces recurrent fetal loss to under 30%.
Purpose of the Study:
- To review current knowledge on aspirin's role in antiphospholipid syndrome.
- To identify areas where aspirin's use is well-demonstrated and where further research is needed.
- To discuss future prospects for aspirin therapy in antiphospholipid syndrome.
Main Methods:
- Review of current literature and clinical experience.
- Analysis of aspirin's efficacy in obstetric complications and thrombosis prevention.
- Discussion of existing guidelines and future research directions.
Main Results:
- Low-dose aspirin is beneficial for preventing pregnancy loss in antiphospholipid antibody syndrome.
- High-dose warfarin (INR ≥ 3) is effective in preventing recurrent thrombosis.
- Aspirin's superiority over warfarin for stroke recurrence prevention in antiphospholipid antibody syndrome is unclear, except in Sneddon's syndrome.
Conclusions:
- Aspirin is crucial for preventing obstetric complications in antiphospholipid antibody syndrome.
- Further prospective studies are required to evaluate aspirin's role in primary and secondary thrombosis prevention.
- Aspirin's utility in atherosclerotic patients with antiphospholipid antibodies requires further evaluation.